Neuronetics (STIM) Aandeel Koers
Neuronetics Koers
In de afgelopen 9 jaar liet Neuronetics de omzet jaarlijks met 17,8% groeien tot 149,16 Miljoen USD. Bij Neuronetics is de nettowinstmarge met -26,1% ten opzichte van -56,4% enkele jaren geleden gestegen. Het consensus-koersdoel voor Neuronetics op 12 maanden bedraagt 5,00 USD, circa 148,1% boven de huidige koers. Van de 10 analisten geven 9 het aandeel een koopadvies — per saldo een Kopen-consensus.
Neuronetics aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Neuronetics bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Neuronetics
The business model of Neuronetics Inc. focuses on providing innovative medical technology solutions for patients suffering from psychiatric disorders, particularly major depressive disorder (MDD). As a leading medical device company, Neuronetics specializes in developing and commercializing NeuroStar® Advanced Therapy, an FDA-cleared non-invasive transcranial magnetic stimulation (TMS) system. This breakthrough treatment option offers a safe and effective alternative to traditional antidepressant medications. Neuronetics offers a comprehensive approach, combining their advanced TMS technology with clinical support and patient education. By addressing the unmet needs of individuals with MDD, Neuronetics aims to improve the quality of life for patients and enhance mental health treatment outcomes.
Neuronetics Inc is primarily active in the healthcare industry.
The main competitors of Neuronetics Inc in the market include companies such as MagVenture, BrainsWay, and Fisher Wallace.
Neuronetics Inc is a reputable medical device company founded in 2003. Headquartered in Pennsylvania, the company focuses on developing innovative treatments for psychiatric disorders, specifically major depressive disorder (MDD). Neuronetics Inc is widely recognized for its groundbreaking invention, NeuroStar Advanced Therapy system, which utilizes transcranial magnetic stimulation (TMS) to alleviate depressive symptoms. With a commitment to providing non-invasive and effective solutions, Neuronetics Inc has gained significant recognition within the medical community. Over the years, the company has strived to improve patients' well-being and enhance mental health treatment options, solidifying its position as a leader in the field of neuromodulation therapies.
Neuronetics Inc has achieved significant milestones since its inception. The company introduced the NeuroStar Advanced Therapy, an FDA-cleared transcranial magnetic stimulation (TMS) system, which has revolutionized the treatment of depression. Neuronetics Inc expanded its reach by attaining various regulatory clearances globally, allowing patients worldwide to benefit from TMS therapy. The company also secured multiple strategic partnerships, further enhancing its market presence and advancing the field of neuromodulation. Neuronetics Inc's dedication to research and innovation has led to numerous clinical publications highlighting the effectiveness of NeuroStar TMS therapy. With its relentless pursuit of advancing psychiatric care, Neuronetics Inc continues to make significant strides in improving patient outcomes and quality of life.
Neuronetics Inc is primarily present in the United States.
Neuronetics Inc represents values of innovation, patient-centricity, and continuous improvement. With a corporate philosophy focused on developing advanced solutions for mental health disorders, Neuronetics Inc strives to improve the lives of individuals suffering from depression. The company's NeuroStar Advanced Therapy system, utilizing transcranial magnetic stimulation, is a testament to their commitment to innovation and providing effective treatment options. By placing patients at the center of their efforts, Neuronetics Inc aims to enhance mental health outcomes and restore hope for those in need.
Analisten hanteren momenteel een gemiddeld koersdoel van 5,00 USD voor het aandeel Neuronetics (mediaan: 5,00 USD), oftewel +148,1 % ten opzichte van de laatste koers. De consensus is gebaseerd op 10 analistenratings.
10 analisten beoordelen het aandeel Neuronetics momenteel: 9 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat Neuronetics een omzet van 161,83 Miljoen USD en winst per aandeel van -0,33 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Neuronetics op 1,80 EUR (2,02 USD).
Het aandeel Neuronetics (STIM) is genoteerd aan 3 beurzen, waaronder: NASDAQ (STIM), Frankfurt (NRC.F), München (NRC.MU).
Neuronetics Inc. is a leading manufacturer of medical devices that help patients with mental disorders such as depression. The company is headquartered in Malvern, Pennsylvania, USA. Neuronetics Inc.'s business model is based on selling devices for Transcranial Magnetic Stimulation (TMS). TMS is a non-invasive method for treating severe depression in patients who have not responded to other treatment methods. The method uses high-intensity magnetic pulses to stimulate the brain, resulting in a reduction of symptoms. The company's core product is the NeuroStar Advanced Therapy System (ATS). The system consists of a TMS device and a specialized treatment chair. The chair can be individually adjusted to meet the patient's needs for optimal treatment. The NeuroStar ATS is the first TMS therapy in the USA to be approved by the Food and Drug Administration (FDA) for use in patients with depression. Neuronetics Inc. distributes its products through a broad sales structure. The company has its own sales representatives who handle the sales and marketing of the products in the USA and Europe. In addition, Neuronetics Inc. collaborates with distribution partners to distribute its products in countries where the company is not directly represented. The company also has a strong research component. Neuronetics Inc. has established a network of clinics and research institutions that participate in clinical studies on TMS therapy. The company also supports independent researchers working on the development of new applications of TMS therapy. Neuronetics Inc. works closely with health insurance companies and private insurers to ensure that its products can be used by as many patients as possible. The company maintains constant contact with healthcare decision-makers and organizes regular conferences and workshops to inform about the possibilities of TMS therapy. In summary, Neuronetics Inc. is an innovative company dedicated to the treatment of patients with severe depression. The company offers a high-quality and safe treatment system that has already been successfully used by many patients. With its broad sales structure and strong research component, Neuronetics Inc. is well positioned to continue to play a leading role in the market for TMS therapy.
De verwachte omzet van Neuronetics bedraagt 161,83 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Neuronetics bedraagt -22,98 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Neuronetics bedraagt momenteel -6,03. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Neuronetics-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Neuronetics bedraagt momenteel 0,86. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Neuronetics-aandeel.
De Eulerpool Kwaliteitsscore voor Neuronetics is 3/10.
De ISIN van Neuronetics is US64131A1051. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Neuronetics is A2JPMY. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Neuronetics is STIM. Onder dit beurstickersymbool wordt het Neuronetics-aandeel op de beurs verhandeld.
Neuronetics aandeel
Neuronetics Peer Group
Neuronetics Ticker
Neuronetics FIGI
Alle fundamentals en diepgaande analyse van Neuronetics
Onze aandelenanalyse van het Neuronetics-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Neuronetics. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: